FDA accepts Loxo approval application for biomarker-driven cancer drug
If approved, LOXO-101 (larotrectinib) would be the second drug to win a biomarker-based label, after Merck's Keytruda.
Drugmakers increasingly target “baskets” of tumors based on mutations
A new report shows a steady growth in so-called "basket studies" in oncology, along with growing interest by the drug industry.
presented by
The Top 6 Best Analytics Tools for Health Care Revenue in 2025
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Loxo Oncology’s shares shoot up on early data slated for ASCO presentation
Loxo's data highlight growing industry interest in so-called "basket" trials and drugs that targeted to genetic markers instead of tumor types.
Roche’s $1.7B precision medicine acquisition of Ignyta targets cancers with rare mutations
Ignyta's lead molecule, entrectinib, is currently in Phase 2 clinical trials targeting rare mutations in non small cell lung cancer and solid tumors.